In the news

OncoHost lunches non-small cell lung cancer test in U.S.

Original source here.

OncoHost, a diagnostics company centered on predictive biomarker development for improved patient care has launched its PROphet non-small cell lung cancer (NSCLC) Test in the United States.

OncoHost’s first test, PROphet NSCLC, guides first-line treatment decisions for advanced unresectable non-small lung cancer patients.

The PROphet NSCLC Test provides clinicians with actionable clinical insights into optimal first-line therapeutic choices and a better understanding of their patients’ personalized cancer dynamics. Requiring just one pre-treatment blood test, PROphet scans approximately 7,000 proteins in a patient’s blood plasma and delivers a report that predicts their clinical benefit from anti-PD-1/PD-L1 immunotherapy-based treatment plans.

Dr. Ofer Sharon, CEO of OncoHost, said: “After years of research, development, and determination, we are proud to launch our PROphet NSCLC test in the United States. While driver mutation detection is an essential factor in determining effective treatment, approximately 85% of all patients diagnosed with NSCLC do not have any detectable driver mutations. In these cases, the PROphet NSCLC Test, combined with PD-L1 results, will serve an invaluable purpose in predicting the best treatment plan for each patient. We hope to create a shift in the industry and improve the lives of those fighting this disease.”

The PROphet algorithm is trained on OncoHost’s large-scale clinical trial, PROPHETIC. To date, the trial has over 1,500 patients recruited across 40 sites worldwide, making it one of the largest prospective cohorts in the precision oncology field. The PROphet NSCLC test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans.

Chris Dingman, OncoHost CCO, added: “We are thrilled to be launching the PROphet NSCLC test, offering a predictive biomarker to guide treatment planning for this large subset of patients. Access to our test will have a significant impact on patient care and treatment protocols. The PROphet Report will guide physicians’ treatment decisions by offering personalized insights on the predicted clinical benefit of immunotherapy. Combining these findings with the patient’s PD-L1 level will allow them to offer the most effective plan and avoid unnecessary treatments.”

Contact us

US office

1110 SE Cary Parkway, Suite 205
Cary, North Carolina
T. (855) 950-2112

Israel office

17 Hamelacha Street, Floor 1
Binyamina, Israel
T. +972 485 37558

Please Note:
PROphet® NSCLC is currently available in all US states except NY